Jean-Michel Paradis1, Hersh S Maniar2, John M Lasala2, Susheel Kodali3, Mathew Williams4, Brian R Lindman2, Ralph J Damiano2, Marc R Moon2, Raj R Makkar5, Vinod H Thourani6, Vasilis Babaliaros6, Ke Xu7, Girma Minalu Ayele7, Lars Svensson8, Martin B Leon3, Alan Zajarias2. 1. Quebec Heart and Lung Institute, Quebec, Canada; Cardiovascular Research Foundation, New York, New York. Electronic address: jm.paradis@criucpq.ulaval.ca. 2. Washington University School of Medicine, St Louis, Missouri. 3. Cardiovascular Research Foundation, New York, New York; Columbia University Medical Center, New York, New York. 4. New York University Langone Medical Center, New York, New York. 5. Cedars Sinai Heart Institute, Los Angeles, California. 6. Emory University School of Medicine, Atlanta, Georgia. 7. Cardiovascular Research Foundation, New York, New York. 8. Cleveland Clinic Foundation, Cleveland, Ohio.
Abstract
OBJECTIVES: This study sought to clarify the clinical and echocardiographic prognostic implication of myocardial injury after transcatheter aortic valve replacement (TAVR). BACKGROUND: The clinical significance of cardiac biomarker elevation after TAVR remains unclear. METHODS: Patients treated with TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) trial were divided into tertiles (T1, T2, T3) based on the difference between the values on post-procedure day 1 and the baseline values of 2 cardiac biomarkers: cardiac troponin I (ΔcTnI); and creatine kinase-myocardial band (ΔCK-MB) fraction. Patients were stratified according to their access route: transfemoral (TF) (n = 1,840) or transapical (TA) (n = 1,173). RESULTS: At 30 days after TF-TAVR, patients in the highest tertile (T3) of cardiac biomarker elevation had a higher rate of all-cause mortality (ΔcTnI: T3: 5.4% vs. T1: 0.5%, p = 0.006; ΔCK-MB: T3: 5.7% vs. T1: 0.9%, p = 0.006) and cardiovascular mortality (ΔcTnI: T3: 4.9% vs. T1: 0.5%, p = 0.01; ΔCK-MB: T3: 3.9% vs. T1: 0.5%, p = 0.02). At 1 year, only patients in the highest CK-MB tertile had higher rates of all-cause (25.4% vs. 16.8%, p = 0.02) and cardiovascular (10.3% vs. 5.0%) mortality. Multivariable analysis demonstrated that greater release of cardiac biomarkers was independently associated with increased mortality in the TF population. After TA-TAVR, being in the highest tertile of cardiac biomarker elevation had no influence on clinical and echocardiographic outcomes at 30 days and 1 year. CONCLUSIONS: After TF-TAVR, a greater degree of myocardial injury was associated with higher rates of 30-day all-cause and cardiovascular mortality. At 1 year, being in the highest tertile of ΔCK-MB was correlated with a higher rate of all-cause and cardiac mortality. Finally, the level of myocardial injury after TA-TAVR had no impact on clinical and echocardiographic outcomes.
RCT Entities:
OBJECTIVES: This study sought to clarify the clinical and echocardiographic prognostic implication of myocardial injury after transcatheter aortic valve replacement (TAVR). BACKGROUND: The clinical significance of cardiac biomarker elevation after TAVR remains unclear. METHODS:Patients treated with TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) trial were divided into tertiles (T1, T2, T3) based on the difference between the values on post-procedure day 1 and the baseline values of 2 cardiac biomarkers: cardiac troponin I (ΔcTnI); and creatine kinase-myocardial band (ΔCK-MB) fraction. Patients were stratified according to their access route: transfemoral (TF) (n = 1,840) or transapical (TA) (n = 1,173). RESULTS: At 30 days after TF-TAVR, patients in the highest tertile (T3) of cardiac biomarker elevation had a higher rate of all-cause mortality (ΔcTnI: T3: 5.4% vs. T1: 0.5%, p = 0.006; ΔCK-MB: T3: 5.7% vs. T1: 0.9%, p = 0.006) and cardiovascular mortality (ΔcTnI: T3: 4.9% vs. T1: 0.5%, p = 0.01; ΔCK-MB: T3: 3.9% vs. T1: 0.5%, p = 0.02). At 1 year, only patients in the highest CK-MB tertile had higher rates of all-cause (25.4% vs. 16.8%, p = 0.02) and cardiovascular (10.3% vs. 5.0%) mortality. Multivariable analysis demonstrated that greater release of cardiac biomarkers was independently associated with increased mortality in the TF population. After TA-TAVR, being in the highest tertile of cardiac biomarker elevation had no influence on clinical and echocardiographic outcomes at 30 days and 1 year. CONCLUSIONS: After TF-TAVR, a greater degree of myocardial injury was associated with higher rates of 30-day all-cause and cardiovascular mortality. At 1 year, being in the highest tertile of ΔCK-MB was correlated with a higher rate of all-cause and cardiac mortality. Finally, the level of myocardial injury after TA-TAVR had no impact on clinical and echocardiographic outcomes.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Martin B Leon; Nicolo Piazza; Eugenia Nikolsky; Eugene H Blackstone; Donald E Cutlip; Arie Pieter Kappetein; Mitchell W Krucoff; Michael Mack; Roxana Mehran; Craig Miller; Marie-angéle Morel; John Petersen; Jeffrey J Popma; Johanna J M Takkenberg; Alec Vahanian; Gerrit-Anne van Es; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys Journal: J Am Coll Cardiol Date: 2011-01-07 Impact factor: 24.094
Authors: N Greenson; J Macoviak; P Krishnaswamy; R Morrisey; C James; P Clopton; R Fitzgerald; A S Maisel Journal: Am Heart J Date: 2001-03 Impact factor: 4.749
Authors: K Martijn Akkerhuis; John H Alexander; Barbara E Tardiff; Eric Boersma; Robert A Harrington; A Michael Lincoff; Maarten L Simoons Journal: Circulation Date: 2002-02-05 Impact factor: 29.690
Authors: Lars G Svensson; Todd Dewey; Samir Kapadia; Eric E Roselli; Alan Stewart; Matt Williams; William N Anderson; David Brown; Marty Leon; Bruce Lytle; Jeffrey Moses; Michael Mack; Murat Tuzcu; Craig Smith Journal: Ann Thorac Surg Date: 2008-07 Impact factor: 4.330
Authors: Benjamin J Freda; W H Wilson Tang; Frederick Van Lente; W Franklin Peacock; Gary S Francis Journal: J Am Coll Cardiol Date: 2002-12-18 Impact factor: 24.094
Authors: Hans Erik Bøtker; Derek Hausenloy; Ioanna Andreadou; Salvatore Antonucci; Kerstin Boengler; Sean M Davidson; Soni Deshwal; Yvan Devaux; Fabio Di Lisa; Moises Di Sante; Panagiotis Efentakis; Saveria Femminò; David García-Dorado; Zoltán Giricz; Borja Ibanez; Efstathios Iliodromitis; Nina Kaludercic; Petra Kleinbongard; Markus Neuhäuser; Michel Ovize; Pasquale Pagliaro; Michael Rahbek-Schmidt; Marisol Ruiz-Meana; Klaus-Dieter Schlüter; Rainer Schulz; Andreas Skyschally; Catherine Wilder; Derek M Yellon; Peter Ferdinandy; Gerd Heusch Journal: Basic Res Cardiol Date: 2018-08-17 Impact factor: 17.165
Authors: Marvin H Eng; Pedro Villablanca; Tiberio Frisoli; Adam B Greenbaum; William W O'Neill Journal: Curr Cardiol Rep Date: 2019-10-31 Impact factor: 2.931
Authors: Hardy Baumbach; Eva R Schairer; Kristina Wachter; Christian Rustenbach; Samir Ahad; Alina Stan; Stephan Hill; Peter Bramlage; Ulrich F W Franke; Tim Schäufele Journal: BMC Cardiovasc Disord Date: 2019-05-14 Impact factor: 2.298
Authors: Yukari Kobayashi; Juyong B Kim; Kegan J Moneghetti; Michael Fischbein; Anson Lee; Claire A Watkins; Alan C Yeung; David Liang; Mehmet O Ozen; Utkan Demirci; Raffick Bowen; William F Fearon; Francois Haddad Journal: Sci Rep Date: 2019-10-17 Impact factor: 4.379